Englander Institute for Precision Medicine

Publications

Found 20 results
Author Title Type [ Year(Asc)]
Filters: Author is Faltas, Bishoy M  [Clear All Filters]
2024
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam H-M et al..  2024.  A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nat Genet. 56(3):371-376.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
2023
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J et al..  2023.  Immunotherapy in the Treatment of Localized Genitourinary Cancers.. JAMA Oncol. 9(10):1447-1454.
Borregales LD, Venkat S, Calderon LPosada, Lewicki P, Flynn T, Faltas BM, Molina AM, Golombos DM, O'Malley P, Scherr DS.  2023.  A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.. Eur Urol. 84(6):604-606.
2022
Liu W, Faltas BM.  2022.  Loss of function mutations in are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma.. Am J Cancer Res. 12(5):2419-2421.
Yu H, Sfakianos JP, Wang L, Hu Y, Daza J, Galsky MD, Sandhu HS, Elemento O, Faltas BM, Farkas AM et al..  2022.  Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT-Stromal and Tgfβ-Dependent Mechanisms.. Mol Cancer Ther. 21(11):1729-1741.
2021
Shohdy KS, Bareja R, Sigouros M, Wilkes DC, Dorsaint P, Manohar J, Bockelman D, Xiang JZ, Kim R, Ohara K et al..  2021.  Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors.. NPJ Genom Med. 6(1):66.
Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.
2020
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.
Vlachostergios PJ, Faltas BM, Carlo MI, Nassar AH, Alaiwi SAbou, Sonpavde G.  2020.  The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.. Cancer Treat Res Commun. 23:100165.
Sfakianos JP, Daza J, Hu Y, Anastos H, Bryant G, Bareja R, Badani KK, Galsky MD, Elemento O, Faltas BM et al..  2020.  Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.. Nat Commun. 11(1):2540.
Hassler MR, Bray F, Catto JWF, Grollman AP, Hartmann A, Margulis V, Matin SF, Roupret M, Sfakianos JP, Shariat SF et al..  2020.  Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.. Eur Urol. 78(2):209-220.
2019
Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al..  2019.  Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3
Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.
Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.
Persi E, Prandi D, Wolf YI, Pozniak Y, Barnabas GD, Levanon K, Barshack I, Barbieri C, Gasperini P, Beltran H et al..  2019.  Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.. Proc Natl Acad Sci U S A. 116(34):16987-16996.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.
2017
Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized and Cancer Models to Guide Precision Medicine.. Cancer Discov. 7(5):462-477.
2016
Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.